Corient Private Wealth
STLN

Corient Private Wealth’s Starling Oncology STLN Stock Holding History

Corient Private Wealth’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,500
Closed -$21K – 2053
2022
Q4 		$21K Buy
+12,500
New +$35.1K ﹤0.01% 1668

Other funds holding STLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Corient Private Wealth's STLN Position: Q1 2023 in Review

Corient Private Wealth sold out of Starling Oncology (STLN) in Q1 2023, closing a stake of 12,500 shares — an estimated $21K sold.

Corient Private Wealth first reported a position in STLN in Q4 2022 and held it in 1 quarter. The position peaked at $21K in Q4 2022. 39 funds tracked by Wall St. Rank hold STLN as of Q1 2023.

  • Corient Private Wealth reported no remaining Starling Oncology position as of Q1 2023 after selling out during the quarter.
  • Corient Private Wealth sold 12,500 Starling Oncology shares in Q1 2023, an estimated $21K.
  • Corient Private Wealth first reported a position in Starling Oncology in Q4 2022 and held it in 1 quarter.
  • Corient Private Wealth's Starling Oncology position peaked at $21K in Q4 2022.
  • 39 funds tracked by Wall St. Rank held Starling Oncology as of Q1 2023.

Based on Corient Private Wealth's 13F filing for Q1 2023, filed 15 May 2023.